Active Biotech AB Interim report January - September 2015

November 6, 2015 08:30 (CET)

Laquinimod

  • The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
  • The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington's disease, are proceeding as planned

Tasquinimod     

  • The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS

ISI          

  • Only commercial activities will be conducted from 2016

Financial summary

MSEK   July - Sept.     Jan. - Sept.   Jan. - Dec.
  2015 2014   2015 2014   2014  
                 
Net sales 5.2 2.6   11.3 7.5   10.4  
                 
Operating loss -22.2 -55.7   -149.7 -172.8   -228.5  
                 
Loss for the period -23.4 -56.6   -152.7 -174.5   -231.5  
                 
Loss per share, before and after dilution (SEK) -0.26 -0.76   -1.70 -2.33   -3.02  
                 
Cash and cash equivalents (at the end of the period)        132.4 161.0   328.5  

For further information, please contact:     

  Tomas Leanderson, 
  President and CEO
  Tel: +46 (0)46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

 

  The report is also available at www.activebiotech.com.

Active Biotech AB Interim report January - September 2015